Hemolytic Anemia
Hematology·MeSH: Anemia, Hemolytic
Prevalence
5.0 / 100K
9 drugs in development·7 companies·1 clinical trial
Drug Pipeline by Phase
Approved(2)
Phase 3(3)
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| CTX112 | CRISPR Therapeutics AG (CRSP) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| zugo-cel | CRISPR Therapeutics AG (CRSP) |
Compare drugs
Frequently asked questions
How many drugs are in development for Hemolytic Anemia?
BioSniper tracks 9 drugs in development for Hemolytic Anemia across 7 companies.
How many clinical trials target Hemolytic Anemia?
There are 1 clinical trial targeting Hemolytic Anemia tracked by BioSniper.
What is the prevalence of Hemolytic Anemia?
The estimated prevalence of Hemolytic Anemia is approximately 5.0 per 100,000 population.
Deep-dive into Hemolytic Anemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis